US2020054742A1PendingUtilityA1
Low, immune enhancing, dose mtor inhibitors and uses thereof
Est. expiryNov 13, 2033(~7.3 yrs left)· nominal 20-yr term from priority
A61K 31/436A61P 37/04A61P 3/10A61P 9/12A61P 43/00A61P 9/10A61P 9/00A61P 25/14A61P 35/02A61P 31/04A61P 35/00A61P 31/16A61P 27/12A61P 27/16A61P 3/04A61P 25/28A61P 19/10A61P 19/02A61P 15/00A61P 25/00A61P 11/00A61P 13/12A61P 13/08A61P 17/00A61P 21/00A61K 45/06A61K 31/4745A61K 39/09A61K 31/519C12N 7/00A61K 39/12A61K 39/145C12N 2760/16034A61K 2039/55511A61K 39/092G01N 33/6854A61K 39/39A61K 39/00
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
Claims
exact text as granted — not AI-modified1 - 15 . (canceled)
16 . A method of promoting an immune response in a human subject suffering from an age-related condition, comprising administering to the human subject suffering from an age-related condition a low, immune enhancing, dose of about 0.1 mg of RAD001, orally and once daily, thereby enhancing or promoting an immune response in the human suffering from an age-related condition.
17 . The method of claim 16 , wherein the human subject suffering from an age-related condition is immunocompromised.
18 . The method of claim 16 , wherein the human subject suffering from an age-related condition has an infectious disease.
19 . The method of claim 16 , wherein the human subject suffering from an age-related condition has an impaired immune response.
20 . The method of claim 16 , wherein the human subject suffering from an age-related condition is immunosenescent.
21 . The method of claim 16 , wherein the age related condition is selected from the group consisting of sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis, osteoarthritis, high blood pressure, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, diminished life expectancy, impaired kidney function, and age-related hearing loss, aging-related mobility disability, cognitive decline, memory impairment, tendon stiffness, heart dysfunction, immunosenescence, cancer, obesity, and diabetes.
22 . The method of claim 21 , wherein the aging-related mobility disability is frailty.
23 . The method of claim 21 , wherein the dementia is age-related dementia.
24 . The method of claim 21 , wherein the heart dysfunction is cardiac hypertrophy or systolic or diastolic dysfunction.Join the waitlist — get patent alerts
Track US2020054742A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.